SPHINX31 (SPHINX 31) is a potent, selective, ATP competitive inhibitor of Serine/arginine-protein kinase 1 (SRPK1) with IC50 of 5.9 nM.
SPHINX31 displays no significant activity against other splicing modulating kinases (CLK family, DYRK1A and DYRK2, DYRK5, SRPK-2/3, PIM1, PIM2 kinases).
SPHINX31 inhibits SRPK1 mediated SRSF1 phosphorylation in PC3 prostate cancer cells with EC50 of 360 nM, dose-dependently switches splicing from VEGF-A165a to VEGF-A165b in RPE cells.
SPHINX31 potently inhibits blood vessel growth in models of choroidal angiogenesis in vivo.
